Compare Biogen Inc (BIIB) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs OneSpan Inc — how do they compare? Biogen Inc trades at $207.56 (market cap $30.13B), while OneSpan Inc trades at $16.19 (market cap $600.69M). The key difference: Biogen Inc is far larger — about 50.2× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | OSPN | |
|---|---|---|
Market Cap | $30.13B | $600.69M |
Sector | Health | Technology |
52-Week High | $216.63 | $16.78 |
52-Week Low | $128.93 | $10.15 |
Enterprise Value | $37.20B | $569.77M |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
OneSpan (OSPN) trades at $16.17, down 1.22% today, with strong fundamental metrics including a P/E of 9.21 and net income margin of 27.76%. The stock shows bullish technical signals with recent earnings beats and analyst consensus pointing to upside potential. Recent product launches like DigipassONE demonstrate ongoing innovation in authentication solutions.
The outlook remains positive with 67% analyst buy ratings and a $17.00 consensus target. Risks include declining operating cash flow and competitive pressure in the software security space. The stock offers value characteristics with reasonable valuation multiples and consistent dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
